CompletedNCT06419608

Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

Researchers compared BHV-7000 and placebo to find out how the approaches affected depression symptoms in people with depression.

Medication studyAges 18–75United States

The study in practice

Understand this study

Researchers compared BHV-7000 and placebo to find out how the approaches affected depression symptoms in people with depression.

This study was for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.

Listed locations: Phoenix, United States · Little Rock, United States and 55 more locationsSee all locations and recruitment
Activities: Medication described in the protocol · Placebo comparator
Compensation: Payment and expense reimbursement have not been verified.

Study clarity

Study start dateStarted: May 28, 2024

Recruitment status: Completed
Enrollment listed in the registry: 336
Sponsor: Biohaven Therapeutics Ltd.
Sponsor type: Biotech company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: United States
Age range: From 18 Years to 75 Years
Official registry ID: NCT06419608
Official title: Show the full official title
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of BHV-7000 Monotherapy in Major Depressive Disorder

Completed

Phoenix · Little Rock · Rogers

54 more locations

FAQ

What did researchers investigate?

Researchers compared BHV-7000 and placebo to find out how the approaches affected depression symptoms in people with depression.

Who is behind this study?

The study sponsor is Biohaven Therapeutics Ltd.

Did this study involve medication?

Yes. The study involved medication, including BHV-7000 and Placebo.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.